IL-17, IL-23 Therapies Lead Psoriasis Care - Quiz - MDSpire

IL-17, IL-23 Therapies Lead Psoriasis Care

Network meta-analysis suggests higher PASI 90 response rates with biologics vs oral systemic therapies

  • By

  • Andrea Surnit

  • April 12, 2026

  • 3 min

Share

Original Source(s)

IL-17, IL-23 Therapies Lead Psoriasis Care

  • by Andrea Surnit

  • April 12, 2026

Related Content

Letter to the Editor Regarding “Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis”

Modified Delphi Consensus Recommendations for the Management of Psoriasis in Asia–Pacific

Immunobiological Therapy in Moderate-to-Severe Psoriasis: A Retrospective Cohort Study Investigating the Effects of Inadequate Therapeutic Compliance on Drug Survival